Record Revenues For Takeda But Headwinds Coming
Vyvanse, Azilva LOEs
While Japan's largest pharma company reached a number of milestones last fiscal year, it is facing a number of challenges to revenues in 2023, for which it is looking to its core commercial portfolio and pipeline to help drive growth.